Trial reportDrug design, development and therapy2026
Analgesic Efficacy of Different Doses of Esketamine as an Adjuvant to Ropivacaine for Thoracoscopy-Guided Thoracic Paravertebral Block After Thoracoscopic Radical Resection for Lung Cancer: A Prospective Randomized Controlled Trial.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Thoracoscopy-guided thoracic paravertebral block (TG-TPVB) is a new analgesia technique; however, the duration of a single TG-TPVB is short. Esketamine combined with local anesthetics can prolong the duration of nerve block. This study compared the analgesic efficacy of three doses of esketamine combined with ropivacaine for TG-TPVB in patients undergoing thoracoscopic radical resection for lung cancer. Methods: 160 patients were randomly allocated into the control, S1, S2, and S3 groups. All patients received TG-TPVB with 20 mL of study solution. The control group received 0.375% ropivacaine alone, whereas the S1, S2, and S3 groups received 0.375% ropivacaine combined with esketamine at doses of 0.1, 0.2, and 0.3 mg/kg, respectively. The time to first patient-controlled intravenous analgesia (PCIA) demand, postoperative numerical rating scale (NRS) pain scores, sufentanil consumption, effective PCIA demands, recovery outcomes, and adverse events were compared between the four groups. Results: The time to first PCIA demand in the three esketamine groups were longer than in the control group. However, S2 and S3 groups were longer than S1 group. NRS pain scores in the three esketamine groups were lower than in the control group at 6, 12, 24, and 48 h postoperatively. Postoperative sufentanil consumption within 24 h, the number of effective PCIA demands and rescue analgesia administrations within 48 h were lower in the three esketamine groups than in the control group. Wake-up time was longer in the S3 group than in the control, S1, and S2 groups. The times to first ambulation and chest tube removal were shorter in the esketamine groups than in the control group (All Conclusion: Esketamine combined with ropivacaine for TG-TPVB prolonged postoperative analgesia, reduce pain scores, reduced analgesic consumption, and facilitated recovery. Esketamine at 0.2 mg/kg seems to show a good balance effect in many aspects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.